Miragen Therapeutics’ top official last week confirmed that post-myocardial infarction remodeling has joined chronic heart failure as the first two indications the microRNA drugs startup intends to pursue.

Speaking at the Center for Business Intelligence’s Executing on the Promise of RNAi conference, held last week in Cambridge, Mass., Miragen President and CEO Bill Marshall also presented preclinical data from the new program, while stressing the importance of conducting preliminary studies in normal animals before proceeding into disease models.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.

By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.

Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.

In Nature this week: a Danish reference genome, and more.